HEMOPHILIA: THE CLINICAL USE OF ANTIHEMOPHILIC GLOBULIN

Abstract

Article1 March 1947HEMOPHILIA: THE CLINICAL USE OF ANTIHEMOPHILIC GLOBULINGEORGE R. MINOT, F.A.C.P., F. H. L. TAYLORGEORGE R. MINOT, F.A.C.P.Search for more papers by this author, F. H. L. TAYLORSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-26-3-363 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe beneficial effect of whole blood transfusion in hemophilia has been recognized for over 30 years. The marked fall in the coagulation time following the transfusion of normal blood was attributed in 1916 by Minot and Lee1to the platelets. Patek and Stetson reinvestigated the problem in 1936. They confirmed the findings of Minot and Lee but showed that plasma free of formed elements including blood platelets had an effect similar to that of whole blood. Patek and Stetson proposed the thesis that the beneficial effect of whole blood transfusion in hemophilia was due to a factor or factors residing...Bibliography1. MINOTLEE GRRI: The blood platelets in hemophilia, Arch. Int. Med., 1916, xviii, 474. CrossrefGoogle Scholar2. PATEKSTETSON AJRP: Hemophilia: Abnormal coagulation of blood and its relation to blood platelets, Jr. Clin. Invest., 1936, xv, 531. CrossrefGoogle Scholar3. TAYLORDAVIDSONTAGNONADAMSMACDONALDMINOT FHCSHJMAAHGR: Studies in blood coagulation: The coagulation properties of certain globulin fractions of normal human plasma in vitro, Jr. Clin. Invest., 1945, xxiv, 698. CrossrefGoogle Scholar4. MINOTDAVIDSONLEWISTAGNONTAYLOR GRCSJHHJFH: The coagulation defect in hemophilia: The effect, in hemophilia, of the parenteral administration of a fraction of the plasma globulins rich in fibrinogen, Jr. Clin. Invest., 1945, xxiv, 704. CrossrefGoogle Scholar5. POHLETAYLOR FJFH: Coagulation defect in hemophilia. Effect in hemophilia of intramuscular administration of globulin substance derived from normal human plasma, Jr. Clin. Invest., 1937, xvi, 741. CrossrefGoogle Scholar6. POHLETAYLOR FJFH: Coagulation defect in hemophilia. Studies on refractory phase following repeated injections of globulin substance derived from normal human plasma in hemophilia, Jr. Clin. Invest., 1938, xvii, 779. CrossrefGoogle Scholar7. LOZNERKARKTAYLOR ELRMFH: The clot promoting activity in hemophilia of Berkfelded normal human plasma free from fibrinogen and prothrombin, Jr. Clin. Invest., 1939, xviii, 603. CrossrefGoogle Scholar8. LOZNERTAYLOR ELFH: The coagulation defect in hemophilia. Studies on the clot promoting activity associated with plasma euglobulin in hemophilia, Jr. Clin. Invest., 1939, xviii, 821. CrossrefGoogle Scholar9. POHLETAYLOR FJFH: The use of a globulin substance derived from beef plasma as a local hemostatic in hemophilia, Jr. Clin. Invest., 1938, xvii, 667. Google Scholar10. TAGNON HJ: The nature of the mechanism of the shock produced by the injection of trypsin and thrombin, Jr. Clin. Invest., 1945, xxiv, 1. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Massachusetts*Presented at the Twenty-seventh Annual Session of the American College of Physicians, Philadelphia, May 14, 1946.From The Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard) of the Boston City Hospital, and the Department of Medicine, Harvard Medical School. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited by“Whatever Works”: Innovations in the Treatment of Hemophilia in the United States 1783–1950Judith Graham Pool and the discovery of cryoprecipitateHome management of haemophiliaBibliography Articles Cited in CommentariesViral safety of haemophilia treatment productsSafety of coagulation factor concentrates12 Genetically engineered and affinity purified plasma proteinsFactor VIII-Related Antigen and von Willebrand's DiseaseHEMOSTATIC MECHANISMS IN TISSUE INJURYChemistry and clinical uses of the protein components involved in blood clottingEdwin J. Cohn †Hemostatic Mechanisms in Tissue InjuryComplete dental care of the hemophiliacBridge Anticoagulant: A Hitherto Unrecognized Blood Clotting Inhibitor in Haemophilic and Christmas-Disease Plasma. A Simple Method for its DemonstrationSURGERY IN HÆMOPHILIADefects of the clotting mechanism in blood dyscrasias and their significance in oral surgeryEdwin J. Cohn †Edwin J. CohnHaemophilia and Related ConditionsDas BlutThe Contributions of George Richards Minot to Experimental MedicineThe Diagnosis and Management of Hemorrhagic DisordersTreatment of the Bleeding PatientChemistry and clinical uses of the protein components involved in blood clottingHemophiliac: The pre- and postoperative treatmentBlood dyscrasia in otolaryngologyHemostasis and Hemostatic AgentsChemistry and clinical uses of the protein components involved in blood clottingBlood and Its DerivativesThe Plasma Proteins in Disease 1 March 1947Volume 26, Issue 3Page: 363-367KeywordsBlood plasmaBlood transfusionFallsGlobulinsHemophiliaHospital medicineMedical servicesPlateletsResearch laboratories Issue Published: 1 March 1947 PDF downloadLoading ...